Edition:
United Kingdom

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.30EUR
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
€1.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,551,964
52-wk High
€1.62
52-wk Low
€0.42

Latest Key Developments (Source: Significant Developments)

Pharming Group H1 Net Result Turns To Profit of 6.4 Million Euros
Thursday, 26 Jul 2018 

July 26 (Reuters) - Pharming Group NV ::H1 RECORD REVENUE FROM PRODUCT SALES, UP 96% ON 2017.H1 NET RESULT WAS A PROFIT OF EUR 6.4 MILLION (HY 2017: LOSS OF EUR 30.2 MILLION).H1 OPERATING RESULTS IMPROVED 288% TO A PROFIT OF EUR 16.3 MILLION FROM EUR 4.2 MILLION IN HY 2017,.REVENUES FROM PRODUCT SALES FOR HALF YEAR INCREASED BY 96% TO EUR 59.1 MILLION.COMPANY'S CASH POSITION INCREASED FROM EUR 60.0 MILLION AT YEAR-END 2017 TO EUR 66.9 MILLION AT 30 JUNE 2018.H1 TOTAL REVENUES INCREASED BY 94% TO EUR 59.5 MILLION.EXPECTS IN 2018 CONTINUED GROWTH IN REVENUES FROM SALES OF RUCONEST®, MAINLY DRIVEN BY US OPERATIONS.WILL FILE IN Q3 FOR A NEW PHASE I/II STUDY OF RHC1INH IN TREATMENT OF PRE-ECLAMPSIA TO START IN Q4 2018.  Full Article

Pharming Group Q1 Operating Profit Up At 8.2 Million Euros
Thursday, 17 May 2018 

May 17 (Reuters) - PHARMING GROUP NV ::Q1 NET PRODUCT SALES INCREASED BY 93% TO EUR 29.3 MILLION (Q1 2017: EUR 15.2 MILLION) LFL.Q1 TOTAL REVENUES UP 90% AT EUR 29.5 MILLION (INCL. EUR 0.2 MILLION OF LICENSE REVENUE) FROM EUR 15.5 MILLION YEAR AGO.NO FURTHER FINANCIAL GUIDANCE FOR 2018 IS PROVIDED.Q1 OPERATING PROFIT INCREASED BY 110% TO EUR 8.2 MILLION (COMPARED WITH EUR 3.9 MILLION IN Q1 2017).Q1 NET PROFIT OF EUR 3.3 MILLION.RECORDING A NET PROFIT FOR QUARTER FOR FIRST TIME.IN 2018, EXPECTS CONTINUED GROWTH IN REVENUES FROM SALES OF RUCONEST.FOR 2018, SEES POSITIVE QUARTERLY OPERATING RESULTS AND NET RESULTS THROUGHOUT YEAR.  Full Article

Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS.‍FDA INDICATED SBLA IS SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW.‍FDA SET AN ACTION DATE OF SEPTEMBER 21, 2018​.  Full Article

Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - PHARMING GROUP NV ::BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH.CASH BALANCE FOLLOWING CONVERSION (PRIOR TO YEAR-END) WAS €56.0 MILLION.  Full Article

Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS.‍BONDHOLDERS CONVERT 26% (EUR 3.0 MILLION) OF THEIR BONDS INTO PHARMING SHARES​.REDUCES OUTSTANDING AMOUNT OF BONDS TO EUR 8.5 MILLION.ISSUES 10,563,380 SHARES FROM WITHIN AMOUNT ALLOCATED TO CONVERSION OF ORDINARY CONVERTIBLE BONDS.NUMBER OF SHARES ISSUED REPRESENTS 2.0% OF OUTSTANDING SHARES IMMEDIATELY BEFORE ISSUE.  Full Article

Pharming Submits License Application to FDA for Ruconest
Monday, 27 Nov 2017 

Nov 27 (Reuters) - PHARMING GROUP NV ::PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS.‍TWO STUDIES ENROLLED A TOTAL OF 56 PATIENTS AND SHOWED CONSISTENT EFFICACY AND SAFETY RESULTS​.  Full Article

Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - PHARMING GROUP NV ::‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​.‍Q3 OPERATING PROFIT UP TO EUR 8.5 MILLION COMPARED WITH A LOSS OF EUR 3.2 MILLION IN Q3 2016​.‍REVENUES FOR NINE MONTHS TO 30 SEPTEMBER INCREASED TO EUR 56.7 MILLION (2016 EUR 8.7 MILLION)​.‍EXPECTS FY 2017 REVENUES FROM PRODUCT SALES TO EXCEED ANALYSTS' FORECASTS ​.‍POSITIVE CASHFLOWS DURING Q3 INCREASED CASH POSITION TO EUR 38.6 MILLION FROM EUR 25.2 MILLION AT JUNE 30 2017​.9 MONTHS GROSS PROFIT EUR 48.8‍​ MILLION VERSUS EUR 5.5 MILLION YEAR AGO.‍EXPECTS Q4 RESULTS TO EXCEED Q3 SIGNIFICANTLY​.‍EXPECTS ACHIEVEMENT OF CONTINUED OPERATING PROFIT AND POSITIVE CASHFLOWS FOR REMAINING QUARTER​.  Full Article

Pharming Group announces positive data from paediatric clinical trial of Ruconest
Monday, 2 Oct 2017 

Oct 2 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®.‍MEDIAN TIME TO ONSET OF RELIEF WAS 60 MINUTES​.‍MEDIAN TIME TO MINIMAL SYMPTOMS WAS 122 MINUTES​.‍ONLY 3/73 (4%) ATTACKS WERE TREATED WITH A SECOND DOSE OF RUCONEST®.​.‍RUCONEST® WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY​.‍NO PATIENTS WITHDREW FROM STUDY DUE TO ADVERSE EVENTS.​.‍STUDY REPORTED CLINICALLY MEANINGFUL RELIEF OF SYMPTOMS​.  Full Article

Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest
Monday, 11 Sep 2017 

Sept 11 (Reuters) - PHARMING GROUP NV :PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE.TO SUBMIT IN Q4 TO FDA FOR REVIEW BLA EFFICACY SUPPLEMENT (SBLA) TO INCLUDE ROUTINE PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENT AND ADULT PATIENTS WITH HAE​.  Full Article

Pharming Group 8-month product sales rise to 6.2 million euros
Monday, 3 Oct 2016 

Pharming Group Nv : 8-month product sales 6.2 million euros ($6.97 million)versus 5.6 million euros year ago . 8-month operating loss 8.3 million euros versus loss of 8.1 million euros year ago . Expect that both sales and gross profits will continue to improve during remainder of year and that investments in research and development will continue to increase gradually. .Would expect to become profitable at operating level during 2017.  Full Article

BRIEF-Pharming Enters Euronext Amsterdam SmallCap-Index (AScX)

* PHARMING ENTERS THE EURONEXT AMSTERDAM SMALLCAP-INDEX (ASCX) Source text for Eikon: Further company coverage: (Gdynia Newsroom)